Core Viewpoint - The National Medical Products Administration (NMPA) of China has released the "Priority Approval Catalog for High-end Medical Devices (2025 Edition)", which includes eight advanced medical devices for expedited approval, aiming to accelerate the market entry of innovative high-end medical equipment [1]. Group 1: Priority Approval Catalog - The catalog includes advanced medical devices such as the boron neutron capture therapy system, ultra-high field magnetic resonance imaging equipment, medical electron accelerators, and implantable brain-machine interface devices [1][2]. - The NMPA will implement priority approval for the medical devices listed in the catalog according to Article 73, Item 3 of the "Regulations on the Registration and Filing of Medical Devices" [1][5]. Group 2: Device Specifications - The boron neutron capture therapy system is designed to treat malignant tumors that are recurrent or for which there are no other conventional treatment options, utilizing a reaction between neutrons and boron to produce secondary particles that kill cancer cells [2]. - The ultra-high field magnetic resonance imaging equipment has a magnetic field strength greater than 5 Tesla [2]. - The medical electron accelerator integrates magnetic resonance imaging guidance and is used for various therapeutic applications [2]. - The implantable brain-machine interface device captures neural signals from the central nervous system through implanted electrodes, enabling interaction with external control devices for compensating motor and sensory dysfunctions [2]. - The endoscopic surgical control system employs robotic technology for operating surgical instruments through natural orifices [2]. - The transcatheter tricuspid valve repair system is suitable for high-risk patients with severe tricuspid regurgitation who are deemed unsuitable for surgical intervention [2]. - The minimally invasive glaucoma surgery (MIGS) implant establishes a drainage pathway for aqueous humor in the eye [2].

Core Viewpoint - The release of the "Priority Approval Directory for High-end Medical Devices (2025 Edition)" by the National Medical Products Administration (NMPA) signifies a regulatory shift aimed at expediting the approval process for high-end medical technologies while ensuring safety and efficacy [2][3]. Summary by Relevant Sections Overview of Eight High-end Medical Devices - The directory includes eight categories of high-end medical devices spanning tumor radiotherapy, imaging equipment, interventional therapy, surgical robots, neuroregulation, and life support, indicating a focus on both cutting-edge technologies and established fields with clinical or technical gaps [2][4]. Significance of Priority Approval - "Priority approval" does not equate to lowered standards but represents a change in resource allocation within the regulatory framework, aiming to reduce unnecessary time costs while maintaining safety and efficacy [3][5]. - The directory serves as a starting point for technologies to enter a "key review perspective," facilitating earlier clinical validation and commercial data accumulation [3][5]. Implications for Companies - Companies can expect to engage in earlier technical communication with the review system, expedite critical registration milestones, and accelerate commercialization processes [5][6]. - The directory emphasizes the importance of entering verifiable and iterative clinical stages, which can enhance competitive advantages for companies [5][6]. Patient Accessibility - For patients, the priority approval means earlier access to advanced treatment technologies, which can support ongoing innovation by bringing commercial returns forward to fund high-risk medical device research [6][8]. Common Features of the Selected Products - The eight products share common characteristics that provide institutional support for long-term technological pathways rather than merely following market trends [7][8]. Conclusion - The publication of the directory marks the beginning of a collaborative regulatory and innovation process, with future observations focused on which technologies complete clinical validation first and how companies leverage their time advantages into long-term capabilities [8].

Core Viewpoint - The National Medical Products Administration (NMPA) has developed the "Priority Approval Directory for High-end Medical Devices (2025 Edition)" which includes advanced medical devices such as medical electronic accelerators, implantable brain-machine interface devices, and endoscopic surgical control systems [1] Group 1 - The NMPA will implement priority approval for medical device registration applications listed in the directory according to Article 73, Item 3 of the "Regulations on the Registration and Filing of Medical Devices" [1] - The Medical Device Technical Review Center of the NMPA will review the registration application materials for the products in the directory [1] - If the review proposes priority approval, the results will be publicly announced, and if there are no objections, the application will enter the priority approval process [1]